Pivotal phase III trial of resminostat in combination with sorafenib as second-line therapy in patients with advanced liver cancer.
Phase of Trial: Phase III
Latest Information Update: 13 Sep 2012
At a glance
- Drugs Resminostat (Primary) ; Sorafenib
- Indications Liver cancer
- Focus Registrational; Therapeutic Use
- 13 Sep 2012 The trial is expected to begin by mid-2013 according to a 4SC media release.
- 05 Mar 2012 New trial record